Skip to main content
Darkfield

Ransomware victim disclosure

← All victims

FUJIFILM

Claimed by Sarcoma · listed 1 year ago

15m
Age
since listed · data leaked

Status timeline

  1. ListedApr 5, 2025
  2. Data leakeddate unknown

At a glance

Group
Sarcoma
Status
Data leaked
Country
Japan
Sector
Technology
Listed on leak site
Apr 5, 2025

About the victim

AI dossier — public-source company profile

FUJIFILM Corporation is a major Japanese multinational diversified technology company with operations spanning digital imaging, medical systems, photofinishing, graphic systems, and advanced pharmaceutical manufacturing. The company is headquartered in Tokyo with global subsidiaries across North America, Canada, and other regions.

Industry
Photography, Medical Devices, Industrial Imaging & Healthcare Solutions
Address
7-3, Akasaka 9-chome, Minato-ku, Tokyo 107-0052, Japan

Attack summary

Severity: high — Confirmed exfiltration of sensitive pharmaceutical R&D data including investigational anti-cancer drug protocols and clinical trial information. This constitutes regulated/proprietary business data with potential impact on competitive advantage and regulatory status of drug development programs.

The Sarcoma group claims to have exfiltrated data related to FUJIFILM's pharmaceutical research and development, specifically materials concerning liposome formulation research and clinical trials for anti-cancer agents. The leak post excerpt discusses FF-10832 and FF-10850 investigational drugs, immune checkpoint inhibitor combination therapy, and manufacturing operations at FUJIFILM Toyama subsidiary.

high

Data the group says was taken

AI dossier — extracted from the leak post
  • Pharmaceutical R&D documentation
  • Liposome formulation research
  • Clinical trial data (FF-10832, FF-10850)
  • Manufacturing facility information
  • Investigational drug protocols

What the group claims

Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf

Sources

Source

Indexed 1 year ago

This page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.

Is this your supplier? Your competitor? You?

Pro plans monitor your domain, corporate emails, and crypto wallets across every new ransomware leak-site post, breach dump and Telegram callout — alerts within 5 minutes.

Disclosure context

About Sarcoma

Sarcoma is a relatively new ransomware group that emerged in October 2024, operating with apparent financial motivations and demonstrating a broad international targeting approach with at least 140 documented victims across multiple countries and industry sectors. The group's origin and affiliations remain unclear due to its recent emergence, with no publicly documented connections to established ransomware families or confirmation of whether they operate as an independent entity or through a Ransomware-as-a-Service model. Limited public information is available regarding Sarcoma's specific attack methodologies, initial access vectors, or technical capabilities, though their targeting patterns suggest opportunistic rather than highly selective victim selection across diverse industries including manufacturing, business services, agriculture and food production, and technology sectors. The group has shown a particular focus on victims in the United States while also maintaining operations against targets in Italy, Canada, Germany, and Australia, though no specific high-profile attacks or record ransom demands have been publicly documented by major security firms or law enforcement agencies. Given the group's recent emergence in late 2024, Sarcoma appears to remain active with no reported law enforcement disruptions or confirmed rebranding activities at this time. The group has been linked to 150 public disclosures across our corpus. First observed on a leak site on October 9, 2024; most recent post May 12, 2026. The operation is currently active.

Also tracked as: Sarcoma Ransomware Group.

Timeline of this disclosure

  • April 5, 2025FUJIFILM listed by Sarcomaon the group's public leak site

Other recent disclosures by Sarcoma

Sarcoma has been linked to 150 public victims on Darkfield. A sample of the most recent:

See the full Sarcoma dossier →

Sector and geography

This disclosure adds to ransomware activity in the Technology sector, which has 3,549 disclosures indexed across all operators we track. Geographically, FUJIFILM is reported in Japan, a country with 220 ransomware disclosures in our corpus.

If your organisation is affected

A listing by Sarcoma means FUJIFILM appeared on a ransomware extortion site and data attributed to it has been published. If this is your organisation, or a supplier you depend on, the priority is to confirm the intrusion and contain it before the window to act closes.

  • Engage your incident-response team and preserve forensic evidence before remediating — do not wipe affected systems first.
  • Force a password reset and revoke active sessions for exposed accounts; rotate any credentials, API keys or certificates that may have been in the stolen data.
  • Assess regulatory notification duties (GDPR, NIS2, sector regulators) — many carry a 72-hour reporting clock from awareness.
  • Report the incident to your national CERT, JPCERT/CC (Japan), as required for your jurisdiction.
  • Monitor for the data appearing on Sarcoma's leak site and across paste and breach channels, and brief downstream partners who may be exposed through you.

How we know this. Darkfield monitors public ransomware leak sites continuously, archiving every new disclosure and the data later released against the victim. Each entry on this page is sourced from the operator's own publication and cross-checked against complementary OSINT feeds (RansomLook, ransomware.live, RansomWatch). We do not collect or host stolen data — only the metadata, timestamps and screenshots needed to make the public disclosure searchable and accountable. Records here are corrected when the original post is edited, retracted, or merged with another disclosure.